Publications

5808 Results

A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy

Authors
P Liu;J Moon;DS Alberts;BJ Monk;M Brady;M Markman
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#5080
Year
2006
Research Committee(s)
Gynecologic
Study Number(s)
S9701

Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC

Authors
M Markman;PY Liu;S WIlczynski;B Monk;LJ Copeland;D Alberts
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#5005
Year
2006
Research Committee(s)
Gynecologic
Study Number(s)
S9701

SWOG S0202: a phase II trial of gemcitabine and capecitabine in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinoma

Authors
S Iqbal;S McCoy;HJ Lenz;SE Rivkin;J Atkins;CD Blanke
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#4134
Year
2006
Research Committee(s)
Gastrointestinal
Study Number(s)
S0202

A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC); a Southwest Oncology Group (SWOG) trial.

Authors
SK Williamson;J Moon;CH Huang;P Guaglianone;GT Wolf;SG Urba
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#5550
Year
2006
Research Committee(s)
Head and Neck
Study Number(s)
S0420

A phase I pharmacokinetic (PK) study of the epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced malignancies and varying degrees of hepatic impairment. a SWOG early therapeutics committee and NCI organ dysfunction working group trial

Authors
CH Takimoto;PY Liu;H Lenz;S Remick;D Mulkerin;S Mani;TW Synold;RK Ramanathan;P Ivy;AM Davies
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#2004
Year
2006
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S0355

Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): results of a phase II Southwest Oncology Group (SWOG) trial (S0339)

Authors
AM Davies;J McCoy;PN Lara;PH Gumerlock;J Crowley;DR Gandara
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#7017
Year
2006
Research Committee(s)
Lung
Study Number(s)
S0339

Phase II study of Erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST)

Authors
KH Albritton;C Rankin;CM Coffin;N Ratner;GT Budd;SM Schuetze;RL Randall;JE DeClue;EC Borden
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#9518
Year
2006
Research Committee(s)
Sarcoma
Study Number(s)
S0330

Rtog 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-fu vs. gemcitabine (G) for resected pancreatic adenocarcinoma

Authors
WF Regine;KW Winter;R Abrams;H Safran;JP Hoffman;A Konski;AB Benson;JS Macdonald;CG Willett;TA Rich
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#4007
Year
2006
Research Committee(s)
Gastrointestinal
Study Number(s)
R9704

Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimes for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study.

Authors
RP Whitehead;S McCoy;IS Wollner;L Wong;WG Harker;CD Blanke
Journal / Conference
ASCO 2006 Gastrointestinal Cancers Symposium #255
Year
2006
Research Committee(s)
Gastrointestinal
Study Number(s)
S0336

Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study

Authors
RP Whitehead;S McCoy;IS Wollner;L Wong;WG Harker;PM Hoff;PJ Gold;KG Billingsley;CD Blanke
Journal / Conference
Proc of the ASCO, Journal of Clinical Oncology 24(18S):#3598
Year
2006
Research Committee(s)
Gastrointestinal
Study Number(s)
S0336